<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04915846</url>
  </required_header>
  <id_info>
    <org_study_id>TAM4MTM / OZM-098</org_study_id>
    <nct_id>NCT04915846</nct_id>
  </id_info>
  <brief_title>Tamoxifen Therapy for Myotubular Myopathy</brief_title>
  <acronym>TAM4MTM</acronym>
  <official_title>TAM4MTM: A Phase 1/2 Randomized, Placebo-Controlled, Double-Blinded, Single Crossover Study to Determine the Safety and Efficacy of Tamoxifen Therapy for Myotubular Myopathy (XLMTM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>James Dowling</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cures Within Reach</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Joshua Frase Foundation USA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Will Cure USA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mogford Campbell Family Chair Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Myotubular Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Great Ormond Street Hospital Charity</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sparks</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Hospital for Sick Children</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1 / 2, randomized, double-blinded, single cross-over study, with a washout&#xD;
      period between treatment regimens, to test the efficacy and safety of tamoxifen therapy to&#xD;
      improve motor and respiratory function in males with XLMTM.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pre-clinical studies in Mtm1 knockout mice (a model of XLMTM) demonstrated prolonged&#xD;
      survival, increased motor function (including muscle strength), and improved muscle&#xD;
      histopathology with tamoxifen treatment. Based on these data, and the known safety profile of&#xD;
      the drug in humans, we hypothesize that tamoxifen treatment will be safe and will improve&#xD;
      motor and respiratory function in XLMTM patients. This is a randomized, double-blinded,&#xD;
      single crossover clinical trial to test this hypothesis and determine the safety and efficacy&#xD;
      of tamoxifen in improving motor and respiratory function in MTM patients. Each subject will&#xD;
      serve as his own control during the placebo phase of the study. As treatments for XLMTM are&#xD;
      current not available, this study addresses a critical unmet need by testing a therapy that,&#xD;
      if effective, may serve as a primary treatment, or in the future as an adjunct to other&#xD;
      therapies in development.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 18, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Double-blinded, placebo-controlled, single cross-over study with washout period before cross-over</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The study is a placebo-controlled double-blinded design. A select few (pharmacist and study staff in charge of pharmacokinetics) and Data Safety Monitoring Board (DSMB) are unblinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Motor Function Measure 32 (MFM32)</measure>
    <time_frame>Baseline to 15 Months</time_frame>
    <description>Mean change from baseline of Motor Function Measure 32 for subjects aged 4 and older</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders for subjects aged 2-4 years (CHOP INTEND)</measure>
    <time_frame>Baseline to 15 months</time_frame>
    <description>Mean change from baseline of Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders for subjects aged 2-4 years</description>
  </primary_outcome>
  <primary_outcome>
    <measure>10 meter walk test</measure>
    <time_frame>Baseline to 15 months</time_frame>
    <description>Mean change from baseline in velocity in 10 meter walk test for ambulant participants</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in pulmonary function testing scores 1) Forced Expiratory Volume in the first second</measure>
    <time_frame>Baseline to 15 months</time_frame>
    <description>Mean change from baseline in participants without invasive respiratory support</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pulmonary function testing scores 2) Forced Vital Capacity</measure>
    <time_frame>Baseline to 15 months</time_frame>
    <description>Mean change from baseline in participants without invasive respiratory support</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pulmonary function testing scores 3) Peak Cough Flow</measure>
    <time_frame>Baseline to 15 months</time_frame>
    <description>Mean change from baseline in participants without invasive respiratory support</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pulmonary function testing scores 4) Maximum Expiratory Pressure</measure>
    <time_frame>Baseline to 15 months</time_frame>
    <description>Mean change from baseline in participants without invasive respiratory support</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pulmonary function testing scores 5) Maximum Inspiratory Pressure or Sniff Inspiratory Pressure</measure>
    <time_frame>Baseline to 15 months</time_frame>
    <description>Mean change from baseline in participants without invasive respiratory support</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>invasive ventilation - time off ventilation</measure>
    <time_frame>Baseline to 15 months</time_frame>
    <description>Mean change in time off ventilator for participants dependent on invasive respiratory support</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of Adverse Events related to the treatment [ Time Frame: 15 Months ]</measure>
    <time_frame>Baseline to 15 months</time_frame>
    <description>Incidence of serious adverse events and adverse events throughout the study, as assessed by CTCAE v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>micro RNA 133a (miR133a)</measure>
    <time_frame>Baseline to 15 months</time_frame>
    <description>Assess miR133a as a biomarker of XLMTM</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>X Linked Myotubular Myopathy</condition>
  <arm_group>
    <arm_group_label>Drug: ApoTamox 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Tamoxifen (tamoxifen citrate); ApoTamox 10 mg tablets orally twice daily for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (no active ingredients) tablets orally twice daily for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ApoTamox 10mg</intervention_name>
    <description>All participants will receive tamoxifen (ApoTamox) for approximately 6 months (6 months + 1 week). Participants and study staff will be blinded as to whether the participants are starting with the placebo or the drug. Depending on randomization, drug or placebo will be dispensed at the end of the t=0 study visit (Phase 1). Dosing will commence the day after the t=0 study visit. At the end of Phase 1, participants will enter a 'washout' period, when they will cease treatment. After approximately 3 months of washout, participants will cross-over to the other treatment regimen and receive the other interventional product (IP) for the final 6 months of their study participation (Phase 2).</description>
    <arm_group_label>Drug: ApoTamox 10mg</arm_group_label>
    <other_name>Tamoxifen Citrate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo comparator</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA&#xD;
&#xD;
          1. Male&#xD;
&#xD;
          2. Patients ages 2 years and older may participate.&#xD;
&#xD;
          3. XLMTM resulting from a confirmed mutation in the Myotubularin 1 (MTM1) gene&#xD;
&#xD;
          4. Patients over 18 years of age and parent(s)/legal guardian(s) of patients &lt;18 years of&#xD;
             age must provide written informed consent prior to participating in the study and&#xD;
             informed assent will be obtained from minors, or at least 7 years of age when required&#xD;
             by regulation.&#xD;
&#xD;
          5. Willing and able to comply with all protocol requirements and procedures.&#xD;
&#xD;
        EXCLUSION CRITERIA&#xD;
&#xD;
          1. Other disease which may significantly interfere with the assessment of myotubular&#xD;
             myopathy (MTM) and is clearly not related to the disease, at the discretion of the&#xD;
             qualified investigator.&#xD;
&#xD;
          2. Has undergone surgery or hospitalization &lt; 3 months before starting TAM4MTM (at t = -3&#xD;
             months), or has surgery scheduled during the 18 months of participation in TAM4MTM,&#xD;
             which will impede motor assessments in the opinion of the Investigator.&#xD;
&#xD;
          3. Has a history of thromboembolic events&#xD;
&#xD;
          4. Currently enrolled in a treatment study for XLMTM or receiving treatment with an&#xD;
             experimental therapy other than pyridostigmine.&#xD;
&#xD;
          5. Treatment with pyridostigmine for &lt; 6 weeks duration (must be greater than 6 weeks to&#xD;
             be included in TAM4MTM).&#xD;
&#xD;
          6. Use of concomitant medication known to inhibit CYP2D6 and/or CYP3A4, including&#xD;
             clarithromycin, erythromycin, diltiazem, itraconazole, ketoconazole, ritonavir,&#xD;
             verapamil, goldenseal and grapefruit, paroxetine, troleandomycin, rifampin,&#xD;
             phenobarbital, aminoglutethimide, medroxyprogesterone, amiodarone, haloperidol,&#xD;
             indinavir, ritonavir, quinidine, rifampicin, or any selective serotonin reuptake&#xD;
             inhibitor (SSRI).&#xD;
&#xD;
          7. Subject has a contraindication to tamoxifen or its ingredients&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jame J Dowling, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Hospital for Sick Children</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Etsuko Tsuchiya, PhD</last_name>
    <phone>4168137654</phone>
    <phone_ext>309448</phone_ext>
    <email>etsuko.tsuchiya@sickkids.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kim Amburgey, MS</last_name>
    <phone>4168137654</phone>
    <phone_ext>301707</phone_ext>
    <email>kim.amburgey@sickkids.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ann and Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Nancy L Kuntz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Institutes of Health</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Office of patient recruitment</last_name>
      <phone>800-411-1222</phone>
      <phone_ext>TTY8664111010</phone_ext>
      <email>prpl@cc.nih.gov</email>
    </contact>
    <investigator>
      <last_name>Carsten Bonnemann</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Etsuko Tsuchiya, PhD</last_name>
      <phone>4168137654</phone>
      <email>etsuko.tsuchiya@sickkids.ca</email>
    </contact>
    <contact_backup>
      <last_name>Kim Amburgey, MS</last_name>
      <phone>4168137654</phone>
      <email>kim.amburgey@sickkids.ca</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital for Children</name>
      <address>
        <city>London</city>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Giovanni Baranello, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Amburgey K, Tsuchiya E, de Chastonay S, Glueck M, Alverez R, Nguyen CT, Rutkowski A, Hornyak J, Beggs AH, Dowling JJ. A natural history study of X-linked myotubular myopathy. Neurology. 2017 Sep 26;89(13):1355-1364. doi: 10.1212/WNL.0000000000004415. Epub 2017 Aug 25.</citation>
    <PMID>28842446</PMID>
  </reference>
  <reference>
    <citation>Maani N, Sabha N, Rezai K, Ramani A, Groom L, Eltayeb N, Mavandadnejad F, Pang A, Russo G, Brudno M, Haucke V, Dirksen RT, Dowling JJ. Tamoxifen therapy in a murine model of myotubular myopathy. Nat Commun. 2018 Nov 19;9(1):4849. doi: 10.1038/s41467-018-07057-5.</citation>
    <PMID>30451841</PMID>
  </reference>
  <reference>
    <citation>Gayi E, Neff LA, Massana Muñoz X, Ismail HM, Sierra M, Mercier T, Décosterd LA, Laporte J, Cowling BS, Dorchies OM, Scapozza L. Tamoxifen prolongs survival and alleviates symptoms in mice with fatal X-linked myotubular myopathy. Nat Commun. 2018 Nov 19;9(1):4848. doi: 10.1038/s41467-018-07058-4.</citation>
    <PMID>30451843</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 6, 2021</study_first_submitted>
  <study_first_submitted_qc>June 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2021</study_first_posted>
  <last_update_submitted>June 17, 2021</last_update_submitted>
  <last_update_submitted_qc>June 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The Hospital for Sick Children</investigator_affiliation>
    <investigator_full_name>James Dowling</investigator_full_name>
    <investigator_title>Staff clinician and senior scientist</investigator_title>
  </responsible_party>
  <keyword>tamoxifen</keyword>
  <keyword>X-linked myotubular myopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Diseases</mesh_term>
    <mesh_term>Myopathies, Structural, Congenital</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

